The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
New horizons in adjuvants for vaccine development
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
How dying cells alert the immune system to danger
Kono, H., & Rock, K. L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2215 · Cited by 1,737
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Kawai, T., & Akira, S. (2007) · Seminars in Immunology · doi:10.1016/j.smim.2006.12.004 · Cited by 1,404
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Jiang, W., Swiggard, W. J., Heufler, C., Peng, M., Mirza, A., Steinman, R. M., & Nussenzweig, M. C. (1995) · Nature · doi:10.1038/375151a0 · Cited by 964
Stoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
ER–phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells
Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., van Endert, P., & Amigorena, S. (2003) · Nature · doi:10.1038/nature01911 · Cited by 753
Phagosomes are competent organelles for antigen cross-presentation
Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., & Desjardins, M. (2003) · Nature · doi:10.1038/nature01912 · Cited by 699
Self-citationSynthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8
Gorden, K. B., Gorski, K. S., Gibson, S. J., Kedl, R. M., Kieper, W. C., Qiu, X., Tomai, M. A., Alkan, S. S., & Vasilakos, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.3.1259 · Cited by 683
Nanotechnology in vaccine delivery
Peek, L. J., Middaugh, C. R., & Berkland, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.017 · Cited by 562
Targeting the innate immune response with improved vaccine adjuvants
Pashine, A., Valiante, N. M., & Ulmer, J. B. (2005) · Nature Medicine · doi:10.1038/nm1210 · Cited by 555
Mahnke, K., Guo, M., Lee, S., Sepulveda, H., Swain, S. L., Nussenzweig, M., & Steinman, R. M. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.3.673 · Cited by 544
Bojang, K. A., Milligan, P. J., Pinder, M., Vigneron, L., Alloueche, A., Kester, K. E., Ballou, W. R., Conway, D. J., Reece, W. H., Gothard, P., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06957-4 · Cited by 528
Singh, M., & O'Hagan, D. (1999) · Nature Biotechnology · doi:10.1038/15058 · Cited by 506
Wu, Y., Ellis, R. D., Shaffer, D., Fontes, E., Malkin, E. M., Mahanty, S., Fay, M. P., Narum, D., Rausch, K., Miles, A. P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002636 · Cited by 449
Brewer, J. M., Conacher, M., Hunter, C. A., Mohrs, M., Brombacher, F., & Alexander, J. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6448 · Cited by 440
Seubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5402 · Cited by 430
Ackerman, A. L., Kyritsis, C., Tampé, R., & Cresswell, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1735556100 · Cited by 383
Recognition of viruses by innate immunity
Takeuchi, O., & Akira, S. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00562.x · Cited by 342
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Ligand recognition by antigen-presenting cell C-type lectin receptors
McGreal, E. P., Miller, J. L., & Gordon, S. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.12.001 · Cited by 310
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Second-generation vaccines against leishmaniasis
COLER, R., & REED, S. (2005) · Trends in Parasitology · doi:10.1016/j.pt.2005.03.006 · Cited by 266
Self-citationAkira, S. (2006) · Current Topics in Microbiology and Immunology · doi:10.1007/3-540-32636-7_1 · Cited by 256
Ulanova, M., Tarkowski, A., Hahn-Zoric, M., & Hanson, L. Å. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.1151-1159.2001 · Cited by 239
Aggregates Are the Biologically Active Units of Endotoxin
Mueller, M., Lindner, B., Kusumoto, S., Fukase, K., Schromm, A. B., & Seydel, U. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401231200 · Cited by 236
Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
De Donato, S., Granoff, D., Minutello, M., Lecchi, G., Faccini, M., Agnello, M., Senatore, F., Verweij, P., Fritzell, B., & Podda, A. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00138-3 · Cited by 184
Marchand, M., Punt, C. J. A., Aamdal, S., Escudier, B., Kruit, W. H. J., Keilholz, U., Håkansson, L., van Baren, N., Humblet, Y., Mulders, P., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00479-3 · Cited by 169
Straus, S. E., Wald, A., Kost, R. G., McKenzie, R., Langenberg, A. G. M., Hohman, P., Lekstrom, J., Cox, E., Nakamura, M., Sekulovich, R., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514103 · Cited by 169
Monophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines
Baldridge, J. R., & Crane, R. T. (1999) · Methods · doi:10.1006/meth.1999.0834 · Cited by 168
The global impact of vaccines containing aluminium adjuvants
Clements, C. J., & Griffiths, E. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00168-8 · Cited by 164
Harding, C. V., Collins, D. S., Kanagawa, O., & Unanue, E. R. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.9.2860 · Cited by 161
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours
Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 160
Age-related decline in immunity: implications for vaccine responsiveness
Kumar, R., & Burns, E. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.467 · Cited by 160
Chwalek, M., Lalun, N., Bobichon, H., Plé, K., & Voutquenne‐Nazabadioko, L. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2006.05.004 · Cited by 152
Toll or Toll-Free Adjuvant Path Toward the Optimal Vaccine Development
Ishii, K. J., & Akira, S. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9087-x · Cited by 151
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Lee, H.-H., Hoeman, C. M., Hardaway, J. C., Guloglu, F. B., Ellis, J. S., JAIN, R. K., Divekar, R. D., Tartar, D. M., Haymaker, C., & Zaghouani, H. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071371 · Cited by 140
Structural and Immunological Characterization of the Vaccine Adjuvant QS-21
Kensil, C. R., Wu, J., & Soltysik, S. (1995) · Pharmaceutical biotechnology · doi:10.1007/978-1-4615-1823-5_22 · Cited by 139
Rimmelzwaan, G. F., Nieuwkoop, N., Brandenburg, A., Sutter, G., Beyer, W. E., Maher, D., Bates, J., & Osterhaus, A. D. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00310-8 · Cited by 136
Building an immune system from nine domains
Pålsson‐McDermott, E. M., & O'Neill, L. A. J. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351437 · Cited by 130
Miranda‐Verástegui, C., Llanos‐Cuentas, A., Arevalo, I., Ward, B. J., & Matlashewski, G. (2005) · Clinical Infectious Diseases · doi:10.1086/429238 · Cited by 129
Bayry, J., Tchilian, E. Z., Davies, M. N., Forbes, E. K., Draper, S. J., Kaveri, S. V., Hill, A. V. S., Kazatchkine, M. D., Beverley, P. C. L., Flower, D. R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803453105 · Cited by 126
Wu, H., & Russell, M. W. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00168-0 · Cited by 122
The use of oil adjuvants in therapeutic vaccines
Aucouturier, J., Ascarateil, S., & Dupuis, L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.116 · Cited by 120
The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview
Stockfleth, E., Trefzer, U., Garcia-Bartels, C., Wegner, T., Schmook, T., & Sterry, W. (2003) · British Journal of Dermatology · doi:10.1046/j.0366-077x.2003.05626.x · Cited by 119
Ennis, F. A., Cruz, J., Jameson, J., Klein, M. H., Burt, D. S., & Thipphawong, J. (1999) · Virology · doi:10.1006/viro.1999.9765 · Cited by 109
Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]
Keam, S. J., & Harper, D. M. (2008) · Drugs · doi:10.2165/00003495-200868030-00007 · Cited by 107
Vaccinology at the beginning of the 21st century
Wack, A., & Rappuoli, R. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.05.005 · Cited by 104
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Virus-sized vaccine delivery systems
Scheerlinck, J. Y., & Greenwood, D. L. V. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.016 · Cited by 99
Ryan, E. J., McNeela, E. A., Murphy, G. A., Stewart, H., O’Hagan, D. T., Pizza, M., Rappuoli, R., & Mills, K. H. G. (1999) · Infection and Immunity · doi:10.1128/iai.67.12.6270-6280.1999 · Cited by 98
Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children
Bojang, K., Olodude, F., Pinder, M., Ofori‐Anyinam, O., Vigneron, L., Fitzpatrick, S., Njie, F., Kassanga, A., Leach, A. J., Milman, J., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.03.019 · Cited by 95
Edelman, R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.167 · Cited by 92
Ryan, E. T., & Calderwood, S. B. (2000) · Clinical Infectious Diseases · doi:10.1086/313951 · Cited by 85
Synthetic TLR4-active Glycolipids as Vaccine Adjuvants and Stand-alone Immunotherapeutics
Johnson, D. A. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783378882 · Cited by 81
TLR4 agonists as immunomodulatory agents
Alderson, M. R., McGowan, P., Baldridge, J. R., & Probst, P. (2006) · Journal of Endotoxin Research · doi:10.1179/096805106x118753 · Cited by 80
Pichyangkul, S., Gettayacamin, M., MILLER, R., Lyon, J. A., Angov, E., Tongtawe, P., RUBLE, D., HEPPNERJR, D., Kester, K. E., & Ballou, W. R. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.023 · Cited by 69
Nod‐like receptors in innate immunity and inflammatory diseases
Carneiro, L. A. M., Travassos, L. H., & Girardin, S. E. (2007) · Annals of Medicine · doi:10.1080/07853890701576172 · Cited by 68
The development and use of vaccine adjuvants
Edelman, R. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:2:129 · Cited by 66
Influenza virosomes as an efficient system for adjuvanted vaccine delivery
Glück, R., Moser, C., & Metcalfe, I. C. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1139 · Cited by 63
Immunostimulatory DNA as a vaccine adjuvant
Higgins, D., Marshall, J. D., Traquina, P., Nest, G. V., & Livingston, B. D. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.747 · Cited by 62
Development of a leishmaniasis vaccine: the importance of MPL
Reed, S. G., Coler, R. N., & Campos‐Neto, A. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.239 · Cited by 59
Self-citationMcCormack, S., Tilzey, A., Carmichael, A. J., Gotch, F., Kepple, J., Newberry, A. M., Jones, G. J., Lister, S. G., Beddows, S. A., CHEINGSONG-POPOV, R., et al. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00388-6 · Cited by 58
Tuberculosis vaccine development; from mouse to man
Reed, S. G., & Lobet, Y. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.03.011 · Cited by 54
Self-citationByars, N. E., ALLISON, A. C., Harmon, M. W., & Kendal, A. P. (1990) · Vaccine · doi:10.1016/0264-410x(90)90177-n · Cited by 52
Regulation of Antiviral Innate Immune Responses by RIG-I Family of RNA Helicases
Onomoto, K., Yoneyama, M., & Fujita, T. (2007) · Springer eBooks · doi:10.1007/978-3-540-71329-6_10 · Cited by 51
Radošević, K., Rodrı́guez, A., Mintardjo, R., Tax, D., Bengtsson, K. L., Thompson, C., Zambon, M. C. F. A., Weverling, G. J., UytdeHaag, F. G. C. M., & Goudsmit, J. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.071 · Cited by 51
Barackman, J. D., Ott, G. S., Pine, S. O., & O’Hagan, D. T. (2001) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.8.3.652-657.2001 · Cited by 39
Sambhara, S. R., Kurichh, A., Miranda, R., James, O., Underdown, B. J., Klein, M. C. A., Tartaglia, J., & Burt, D. S. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1799 · Cited by 36
A Purified Saponin Acts as an Adjuvant for a T-Independent Antigen
White, A. C., Cloutier, P. A., & Coughlin, R. T. (1991) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-6000-1_22 · Cited by 29
Audibert, F., Parant, M., Damais, C., Lefrancier, P., Derrien, M., Choay, J., & CHEDID, L. A. (1980) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(80)91442-4 · Cited by 24
Vaccines and the cold chain: is it too hot… or too cold?
Burgess, M. A., & McIntyre, P. B. (1999) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1999.tb123527.x · Cited by 21
Cited by
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
A DNA nanodevice-based vaccine for cancer immunotherapy
Liu, S., Jiang, Q., Zhao, X., Zhao, R., Wang, Y., Wang, Y., Liu, J., Shang, Y., Zhao, S., Wu, T., et al. (2021) · Nature Materials · doi:10.1038/s41563-020-0793-6 · Cited by 548
Oyewumi, M. O., Kumar, A., & Cui, Z. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.89 · Cited by 547
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Self-citationRecent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 385
Metadata
- Authors
- Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 30
- Issue
- 1
- Pages
- 23-32
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2062274977
- Cited by
- 618
- References
- 76
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.